WallStSmart

Alibaba Group Holding Ltd (BABA)vsBrilliA Inc (BRIA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Alibaba Group Holding Ltd generates 2133016% more annual revenue ($1.04T vs $48.99M). BABA leads profitability with a 7.0% profit margin vs -0.0%. BABA earns a higher WallStSmart Score of 55/100 (C-).

BABA

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 8.7Quality: 6.5
Piotroski: 2/9Altman Z: 2.02

BRIA

Avoid

24

out of 100

Grade: F

Growth: 2.0Profit: 4.0Value: 5.0Quality: 7.5
Piotroski: 1/9Altman Z: 3.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BABAUndervalued (+65.0%)

Margin of Safety

+65.0%

Fair Value

$435.28

Current Price

$100.36

$334.92 discount

UndervaluedFair: $435.28Overvalued

Intrinsic value data unavailable for BRIA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BABA4 strengths · Avg: 9.8/10
Market CapQuality
$249.37B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4610/10

Growing faster than its price suggests

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

BRIA3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
3.5210/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

BABA4 concerns · Avg: 2.8/10
Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Profit MarginProfitability
7.0%3/10

7.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-79.4%2/10

Earnings declined 79.4%

BRIA4 concerns · Avg: 2.5/10
Market CapQuality
$34.50M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Revenue GrowthGrowth
-34.0%2/10

Revenue declined 34.0%

EPS GrowthGrowth
-96.4%2/10

Earnings declined 96.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : BABA

The strongest argument for BABA centers on Market Cap, PEG Ratio, Price/Book. PEG of 0.46 suggests the stock is reasonably priced for its growth.

Bull Case : BRIA

The strongest argument for BRIA centers on Altman Z-Score, Debt/Equity, Price/Book.

Bear Case : BABA

The primary concerns for BABA are Return on Equity, Profit Margin, Piotroski F-Score.

Bear Case : BRIA

The primary concerns for BRIA are Market Cap, Piotroski F-Score, Revenue Growth.

Key Dynamics to Monitor

BABA profiles as a value stock while BRIA is a turnaround play — different risk/reward profiles.

BABA is growing revenue faster at 8.6% — sustainability is the question.

BRIA generates stronger free cash flow (-922,000), providing more financial flexibility.

Monitor INTERNET RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BABA scores higher overall (55/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alibaba Group Holding Ltd

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Alibaba Group Holding Limited, also known as Alibaba Group and Alibaba.com, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via web portals, as well as electronic payment services, shopping search engines and cloud computing services. It owns and operates a diverse portfolio of companies around the world in numerous business sectors.

BrilliA Inc

CONSUMER CYCLICAL · APPAREL RETAIL · USA

BrilliA Inc. is an innovative biotechnology company dedicated to enhancing skin health and advancing regenerative medicine through cutting-edge solutions for wound healing. By harnessing proprietary technologies, BrilliA addresses significant unmet medical needs, aiming to improve patient quality of life. With a strong commitment to research and development, the company is well-positioned to transform scientific advancements into effective therapeutic products, solidifying its role as a leader in the dynamic healthcare landscape.

Visit Website →

Want to dig deeper into these stocks?